Roivant Sciences Ltd ROIV

$35.53 -0.25 (-0.70%)

Valuation

Market cap
25,844,716,000
Revenue TTM
$8,260,000
Net income TTM
$-299,770,000
PE ratio
0.00
Forward PE
—
Profit margin
-3,629.18%
Debt to equity
0.00

Trading

Volume
5,739,900
Avg volume
7,724,018
Day's range
$34.75 – $36.34
Shares out
722,323,000
Stochastic %K
30%
Beta
1.10
Analysts
Strong Sell
Price target
$48.15

Price

Company profile

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated wit...

Show more

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Industry
Biotechnology
Sector
Healthcare
Phone
44 20 7400 3347
Website
https://roivant.com
Address
50 Broadway, 7th Floor, London, United Kingdom

Latest news

Stocktwits

SmartFlowTrading Oct 7, 12:29 PM
Top 5 bullish options-flow setups from today: $CAT — $2.47M calls, 45 DTE, strikes only ~2% above spot. Cleanest structure of the day. $FSLR — $1.22M calls, 31 DTE, with strong confirmation from recent flow. $ZM — $811K bought calls across two trades, ~41 DTE. Clean upside positioning into the next few weeks. $INTU — $628K calls, 45 DTE. Straightforward directional bullish exposure. $ROIV — $582K calls, 45 DTE, strikes only ~4% above spot. One of the cleaner biotech setups.
0 replies
TradeQuant Oct 6, 7:46 PM
$ROIV Adding 11/20 $37C. ER.
0 replies
renoH4 Oct 2, 10:57 AM
$ROIV $ABUS
0 replies
Quantumup Oct 1, 11:59 AM
Wedbush reiterated $JBIO Outperform-$47 after the Co. reported preliminary preclinical data for JADE301 at EADV and remained on track to kick off a Phase 1 healthy volunteer study in 4Q26. $PFE $ROIV AZN ARGX OTSKY TVTX VERA VRTX NVS Wedbush said in its note: Preclinical JADE301 data demonstrates ~3x longer half-life vs. dazukibart (PFE, not covered). Additionally, the JADE301 SC and IV doses demonstrated similar time/concentration profiles. Phase 1 results will better inform on human dosing and safety. Bottom line, we see the initial data appearing supportive. No change to our JBIO estimates as we continue to leave JADE301 as upside to our estimates. We look ahead to 2027 as an important turning point for JBIO with multiple readouts lining up including initial JUNIPER Phase 2 JADE101 data.
0 replies
Quantumup Sep 30, 7:54 PM
Stifel on $JBIO (Buy; $40): We're reiterating our Buy rating on JBIO following preclinical updates presented at EADV for recently-disclosed JADE301, a half-life extended anti-IFN-ẞ mAb for Dermatomyositis. $PFE $ROIV AZN ARGX OTSKY TVTX VERA ARWR NVS BIIB - RHHBY AMGN Here's what else Stifel had to say in its note to investors: https://x.com/Quantumup1/status/2105385653227721151?s=20
0 replies
StockConsultant Sep 30, 7:43 PM
Before the close, Longs at support Did a quick screen for some good long setups at support: $ANGX $CRDF $RNG and $ROIV stocks at https://www.stockconsultant.com/?ANGX
0 replies
ccdemuth Sep 28, 5:49 PM
$SPCX $KRE $XBI $ROIV $LQDA https://chrisdemuthjr.medium.com/big-boring-bonds-dbc00afb64c6
0 replies
countingguy2006 Sep 24, 5:57 PM
$ROIV Vivek sells $1.2 billion worth of shares and then the stock sells off and stifles with downward action. These games are ridiculous!
1 replies